Celcuity Inc: Clinical Trials

6 trials sponsored by Celcuity Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 13Active not recruiting 1, Recruiting 1, Terminated 1

Follow Celcuity Inc: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male
Phase 1 / Phase 2RecruitingCelcuity Inc542024-01-012026-04-13
Fulvestrant + Neratinib In Breast Cancer
NERATINIB, FULVESTRANT - Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer
Phase 2WithdrawnMassachusetts General Hospital2023-07-012023-08-01
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center102022-08-182025-06-11
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Neratinib - Triple Negative Breast Cancer, Early-stage Breast Cancer
Phase 2UnknownWest Cancer Center272019-06-212023-12-18
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Gedatolisib, Talazoparib - TNBC - Triple-Negative Breast Cancer
Phase 1 / Phase 2Active not recruitingKari Wisinski372019-04-172024-06-07
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
Letrozole, Abemaciclib, LY3023414 - Endometrial Cancer
Phase 2RecruitingDana-Farber Cancer Institute1102018-12-242026-06-22

Conditions studied

Breast Neoplasms (3)  ·  Triple Negative Breast Neoplasms (2)  ·  Endometrial Neoplasms (1)  ·  Genital Diseases, Male (1)  ·  Male Urogenital Diseases (1)  ·  Neoplasm Metastasis (1)  ·  Prostatic Diseases (1)  ·  Prostatic Neoplasms (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)

Interventions

gedatolisib (3)  ·  neratinib (3)  ·  Fulvestrant (1)  ·  LY3023414 (1)  ·  Letrozole (1)  ·  Metformin (1)  ·  abemaciclib (1)  ·  capmatinib (1)  ·  darolutamide (1)  ·  talazoparib (1)

Countries

United States (6)  ·  France (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Aditya Bardia, MD,MPH (1)  ·  Gregory A Vidal, MD.,PhD (1)  ·  Kari Wisinski, MD (1)  ·  Nadene Zack, MS (1)  ·  Panagiotis Konstantininopoulos, MD (1)  ·  Rachel Layman (1)

Results publications

PMID 27713176, PMID 28302091, PMID 36174113, PMID 40471518